FACS Fernando Maluenda MD

Publications (2)4.2 Total impact

• Article: Early gallbladder cancer: Is further treatment necessary?

  FACS Xabier de Aretxabala MD, Ivan Roa MD, FACS Juan Hepp MD, FACS Fernando Maluenda MD, Gerardo Mordojovich MD, Jorge Leon MD, Juan Carlos Roa MD
  [show abstract] [hide abstract]
  ABSTRACT: Background and Objectives The goal of this study was to evaluate a series of patients with early gallbladder cancer, focusing on the selection of treatment and the role of Rokitansky Aschoff sinus infiltration.Methods We performed a retrospective analysis of a prospective series of 371 patients with gallbladder cancer. Specimens were reviewed by an independent pathologist to confirm the diagnosis and depth of infiltration and to evaluate the presence of Rokitansky Aschoff sinus involvement.ResultsForty-nine and 45 patients with muscular (pT1b) and mucosal (pT1a) infiltration gallbladder cancer tumors were studied respectively. Simple cholecystectomy was the treatment in all patients, with the exception of 11 patients who underwent further surgery. Rokitansky Aschoff sinus invasion was seen in seven patients with mucosa (pT1a) and three with muscular (pT1b) compromise. The 5-year survival rates of patients with muscular (pT1b) and mucosal (pT1a) infiltration were 87.6% and 86.4%, respectively. Patients with Rokitansky Aschoff involvement had a lower survival rate than those with no involvement in both categories.Conclusions Early gallbladder cancer is associated with a favorable prognosis and cholecystectomy should be the standard treatment. Despite some patients having a worse prognosis, there are no data to support more aggressive treatment. J. Surg. Oncol. 2009;100:589–593. © 2009 Wiley-Liss, Inc.
  Journal of Surgical Oncology 11/2009; 100(7):589 - 593. · 2.10 Impact Factor
• Article: Chemoradiotherapy in gallbladder cancer

  FACS Xabier de Aretxabala MD, Ivan Roa MD, Marcela Berrios MD, FACS Juan Hepp MD, Jorge Gallardo MD, Andres Cordova MD, Juan Carlos Roa MD, Jorge Leon MD, FACS Fernando Maluenda MD
  [show abstract] [hide abstract]
  ABSTRACT: Gallbladder cancer (GC) is considered a rare disease associated with a poor prognosis. Unfortunately, the low number of cases makes the performance of trials addressing the role of adjuvant, neoadjuvant, and/or palliative therapy difficult. For a long time, the majority of trials were 5-fluorouracil (5 FU)-based, and results were uniformly poor. Since the introduction of Gemcitabine, response rates of approximately 30% have been observed through the use of this drug and new approaches have been tested. In this sense, drugs such as Cisplatin and Capecitabine have been employed concurrently with gemcitabine and/or radiation. Since a recurrence pattern is both distant and local, chernoradiation seems a logical option to deal with the disease. However, at the present time, the lack of valid and scientific evidence means that most of the recommendations originate from trials dealing with other tumors, such as pancreas cancer and biliary tract cancer (BTC). The aforementioned treatment alternatives warrant further evaluation focusing on GC. J. Surg. Oncol. 2006;93:699–704. © 2006 Wiley-Liss, Inc.
  Journal of Surgical Oncology 06/2006; 93(8):699 - 704. · 2.10 Impact Factor